B. Braun Medical Inc. (B. Braun), announced a portfolio of Magnesium Sulfate ready-to-use injectable drug products. The company’s decision to manufacture the Magnesium Sulfate products in Irvine, California, will help ensure the reliable supply of a leading drug for the prevention and control of the seizures associated with preeclampsia and eclampsia.
“Preeclampsia and eclampsia put pregnant women and their babies at risk of preterm birth, serious complications or death,” said Angela Karpf, M.D., Corporate Vice President of Medical Affairs at B. Braun. “Magnesium Sulfate is a proven treatment for seizures associated with preeclampsia and eclampsia but is prone to drug shortages. B. Braun’s ready-to-use products are designed to reduce medication errors and improve efficiencies. Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it.”
The rate of preeclampsia in the US has increased 25% in the last two decades and is a leading cause of maternal and infant illness and death. A significant body of evidence attests to the efficacy of magnesium sulfate to prevent seizures in women with preeclampsia with severe features and eclampsia.
